Terns Pharmaceuticals, Inc.
TERN
Clasificación en acciones
#3584
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the... Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
Precio por acción
$52.95
Última sincronización: 2026-05-15
Capitalización bursátil
$4.77B
Cambio (1 día)
0.00%
Cambio (1 año)
529.61%
País
US
Comercio Terns Pharmaceuticals, Inc. (TERN)
Categoría
Healthcare
EPS de Terns Pharmaceuticals, Inc. (TERN)
EPS a fecha de December 2025 TTM: $-1.03
Según los últimos informes financieros y el precio de las acciones de Terns Pharmaceuticals, Inc., el EPS actual de la empresa (TTM) es $-1.03. Al final del año 2023, la empresa tenía un EPS de $-1.27 una disminución en comparación con al EPS de 2022, que fue de $-1.67.
Historial de EPS de Terns Pharmaceuticals, Inc. desde 2018 hasta 2026
EPS al final de cada año
| Año | EPS | Cambiar |
|---|---|---|
| 2026 (TTM) | $-1.03 | -8.04% |
| 2024 | $-1.12 | -11.81% |
| 2023 | $-1.27 | -23.95% |
| 2022 | $-1.67 | -15.66% |
| 2021 | $-1.98 | 22.98% |
| 2020 | $-1.61 | -41.24% |
| 2019 | $-2.74 | 270.27% |
| 2018 | $-0.74 | 0.00% |
EPS de empresas similares o competidoras
| Empresa | EPS | Diferencia de EPS | País |
|---|---|---|---|
| $17.32 | -1,781.55% |
US
|
|
| $-7.98 | 674.76% |
US
|
|
| $-5.29 | 413.59% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,793.20% |
NL
|
